Richard Mark Kirkner
Tocilizumab shortage continues as pandemic wears on
August 19, 2021
Emergency use authorization of tocilizumab for COVID-19 has led to a global shortage, but supplies for rheumatoid arthritis and other inflammatory conditions are faring better – for now.
Heparin’s COVID-19 benefit greatest in moderately ill patients
August 13, 2021
A multiplatform trial reported that therapeutic heparin improved outcomes in moderately ill COVID-19 patients but not in critically ill patients.
Pneumonia risk soars in heart failure patients, especially HFpEF
April 19, 2021
An analysis of two large trials found that patients with heart failure have an elevated risk of pneumonia and related adverse cardiovascular events.
Study clarifies who gets post–COVID-19 interstitial lung disease
March 3, 2021
A study of post–COVID-19 patients found that the sickest are vulnerable to severe lung disease after discharge, but they respond to steroid therapy.
Infant’s COVID-19–related myocardial injury reversed
December 5, 2020
Children hospitalized for COVID-19 should be tested for heart failure based on a case report of an infant with COVID-19 and reversible myocardial injury.
COVID-19 burdens follow patients after discharge
November 18, 2020
Postdischarge COVID-19 patients have high rates of long-term sequelae from sepsis and other severe respiratory viral illnesses.
Updated heart failure measures add newer meds
November 2, 2020
Updated measures for heart failure account for newer medications, drug titration in cardiac resynchronization therapy, and patient-reported outcomes.
MIS-C cardiac evaluation requires more than EF
September 9, 2020
Children with COVID-19 and multisystem inflammatory syndrome need a thorough coronary work-up to evaluate later-phase cardiac injury and dysfunction.
When viruses collide: Flu season during pandemic
August 26, 2020
Seasonal flu in the midst of the COVID-19 pandemic threatens to overwhelm practitioners, hospitals and the health care system.
PVR reassessed as predictor of heart failure
August 7, 2020
A reconsideration of the accepted benchmark for pulmonary vascular hypertension as a predictor of heart failure may be warranted.